FDA 483 - Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. - November 21, 2024

During an FDA inspection conducted from November 18 to November 21, 2024, at Istituto Biochimico Italiano Giovanni Lorenzini S.p.A.'s corporate headquarters in Aprilia, Italy, an investigator identified a significant compliance issue. The primary finding detailed in the FDA 483 document was the company's failure to submit required annual reports within 60 days of the anniversary date of U.S. approval for several of its approved drug products. This observation indicates a lapse in adherence to regulatory requirements for post-market reporting, which is crucial for maintaining transparency and oversight of approved pharmaceutical products. The FDA's regulatory framework mandates timely submission of these reports to ensure ongoing compliance and patient safety. While the FDA 483 document itself does not dictate immediate punitive actions, it serves as a formal notification of observed deficiencies. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. is now expected to address this observation by either presenting an objection or detailing the corrective actions it plans to implement to rectify the identified reporting failures and ensure future compliance with FDA regulations.